Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT03724968
Title Nivolumab Plus Relatlimab or Ipilimumab in Metastatic Melanoma Stratified by MHC-II Expression
Recruitment Terminated
Gender both
Phase Phase II
Variant Requirements No
Sponsors Elizabeth Davis
Indications

melanoma

Therapies

Nivolumab + Relatlimab

Ipilimumab + Nivolumab

Age Groups: adult | senior
Covered Countries USA


No variant requirements are available.